855738-60-2

Upstream product

• 327046-79-7 tert-butyl (4-bromo-2-nitrophenyl)carbamate 
• 383868-64-2 1-(benzyloxy)-4-bromo-2-nitrobenzene 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 855738-61-3 {4-{6-[(3R)-1-Aza-bicyclo[2.2.2]oct-3-yloxy]-pyridazin-3-yl}-2-nitro-phenyl}-carbamic Acid tert-butyl Ester 
• 855738-77-1 (3R)-3-[5-(4-benzyloxy-3-nitro-phenyl)-pyrimidin-2-yloxy]-1-aza-bicyclo[2.2.2]octane 
• 1473358-24-5 C₂₅H₂₉N₃O₃S 
• 1473358-25-6 C₂₅H₂₈N₄O₅S 
• 1473358-26-7 C₂₆H₂₉N₃O₄S 
• 1473358-28-9 C₂₇H₃₁N₃O₄S 
• 1473358-29-0 C₂₀H₂₁N₃OS 
• 1473358-30-3 C₂₀H₂₀N₄O₃S 
• 1473358-31-4 C₂₁H₂₁N₃O₂S 
• 1473358-33-6 C₂₂H₂₃N₃O₂S 
• 1473358-19-8 C₂₅H₃₂BClN₂O₅ 
• 953434-83-8 tert-butyl (2-(4-(chloromethyl)benzamido)-4-(thiophen-2-yl)phenyl)carbamate 
• 1473358-20-1 C₂₃H₂₂ClN₃O₅S 
• 1473358-21-2 C₂₄H₂₃ClN₂O₄S 

Relevant academic research and scientific papers

SELECTIVE HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Characterization and histone deacetylase inhibitory activity of three novel fluorescent benzamide derivatives

New fluorescent benzamide derivatives were developed by using four different aromatic groups with expanding sizes from thiophene to naphthalene, anthracene, and pyrene in an attempt to identify a novel histone deacetylase (HDAC) inhibitor. The compounds e

BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds which are derivatives of benzamide and suitable in methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions .

FUSED BICYCLOHETEROCYCLE SUBSTITUTED QUINUCLIDINE DERIVATIVES

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+-O-; X is O, S, -NH-, and -N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by a7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Fused bicycloheterocycle substituted quinuclidine derivatives

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O—; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

Fused bicycloheterocycle substituted quinuclidine derivatives

Compounds of formula (I) wherein n is 0, 1, or 2; A is N or N+—O?; X is O, S, —NH—, and —N-alkyl-; Ar1 is a 6-membered aromatic ring; and Ar2 is a fused bicycloheterocycle. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.

3-Quinuclidinyl amino-substituted biaryl derivatives

Compounds of formula (I) wherein A is N or N+—O?; n is 0, 1, or 2; Y is O, S, —NH—, and —N-alkyl-; Ar1 is both 6-membered aromatic rings; Ar2 is 5- or 6-membered aromatic rings with a —NR8R9 group, as defined herein. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions having compounds of formula (I) and methods for using such compounds and compositions.